Loading clinical trials...
Loading clinical trials...
A Phase 2 Safety Study of ATI-502 Topical Solution in Subjects With Moderate to Severe Atopic Dermatitis
Conditions
Interventions
ATI-502
Locations
6
United States
Aclaris Investigational Site
Encinitas, California, United States
Aclaris Investigator Site
San Diego, California, United States
Aclaris Investigator Site
Fridley, Minnesota, United States
Aclaris Investigational Site
Bexley, Ohio, United States
Aclaris Investigational Site
Portland, Oregon, United States
Aclaris Investigator Site
Austin, Texas, United States
Start Date
July 10, 2018
Primary Completion Date
April 25, 2019
Completion Date
April 25, 2019
Last Updated
February 17, 2020
NCT07262983
NCT06389136
NCT06342713
NCT07223697
NCT07290803
NCT07265479
Lead Sponsor
Aclaris Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions